View
49
Download
0
Category
Tags:
Preview:
DESCRIPTION
Alzheimer’s Disease Landscape. James R. Burke, MD, PhD Professor of Medicine (Neurology) Duke University Medical Center 9 th June 2012. Alzheimer’s Disease. Most common cause of dementia Clinical Insidious onset of cognitive decline- prominent memory problems. Pathology Brain atrophy - PowerPoint PPT Presentation
Citation preview
Alzheimer’s Disease LandscapeAlzheimer’s Disease Landscape
James R. Burke, MD, PhDJames R. Burke, MD, PhDProfessor of Medicine (Neurology)Professor of Medicine (Neurology)Duke University Medical CenterDuke University Medical Center
9th June 20129th June 2012
Alzheimer’s DiseaseAlzheimer’s Disease
Most common cause of dementia Clinical
• Insidious onset of cognitive decline- prominent memory problems. Pathology Brain atrophy
• Amyloid plaques• Neurofibrillary tangles
2
EtiologyEtiology
AgeAge GeneticsGenetics
• Autosomal Dominant - rare, Autosomal Dominant - rare, early-onset forms- All are early-onset forms- All are related to mutations in amyloid related to mutations in amyloid pathway.pathway.
• Late-onset AD- Apolipoprotein Late-onset AD- Apolipoprotein E- susceptibility gene. E- susceptibility gene. Individuals who inherit APOE 4 Individuals who inherit APOE 4 form are at increased risk of ADform are at increased risk of AD
AD Roses Sci Am Sci Med 1995, 2:16-25
Kawas C et al. Neurology 2000;54:2072-2077
3
4EpidemiologyEpidemiology
Risk Factors for AD
• Age
• Genetics
• Education
• Head trauma
• Medical conditions:Hypertension, Diabetes mellitus, Hypercholesterolemia, Obesity, Smoking
1950 1980 2000 2020
>65 yrs <65 years
Source: U.S. Census Bureau
World-wide incidence of AD World-wide incidence of AD Ziegler Graham et al., 2008 Alz & Dementia 316-323Ziegler Graham et al., 2008 Alz & Dementia 316-323
AD incidence higher in US, Canada, and Europe
What accounts for differences in disease rates?
Obesity, diabetes, smoking,
hypertension?Lifestyle?Genetics?
Systematic review (1998-2005) AD incidence studies (n=27)
CCMS
5
6Pathology/Pathophysiology:Pathology/Pathophysiology: Biomarkers and pathology precede symptomsBiomarkers and pathology precede symptoms
http://adni.loni.ucla.edu/about/biomarkers/
Braak and Braak
7DiagnosisDiagnosis
• History of insidious onset memory problems
• Impairments on cognitive testing- especially delayed memory
• No focal deficits on neurologic examination
• Neuroimaging- atrophy and absence of significant cerebrovascular disease
8Clinical features of ADClinical features of AD
•MCI due to AD- Forgetful, repetitive questions. No impairment in ADLs (2-5 years)
•Mild AD- Disoriented for date/time, word-finding difficulty, trouble organizing tasks at home and work. May be lost away from home. Depression common (2-4 years)
•Moderate AD- Decline in personal hygiene and dress, unable to perform routine tasks around the house. May wander from home. Agitation and sleep problems common. Cannot be left alone (2-10 years)
•Severe AD- Requires assistance in all ADL (bathing, dressing, feeding and toileting) Falls, infection, malnutrition common. Total care (1-3 years)
Biomarkers in ADBiomarkers in AD 9
Disease burdenDisease burden
10
•AD is the 6th cause of death in the US.
•Average survival after diagnosis is 4 to 8 years
•Impact on family and caregivers World Alzheimer’s Report 2010
Cost Dementia vs National Economies
Alzheimer’s Association
$ Billions
11Treatment optionsTreatment options
• Cholinesterase inhibitors• Donepezil
• Galantamine
• Rivastigmine
• Tacrine
• NMDA receptor antagonist• Memantine
• Caprylidene
No Disease Modifying Therapies
Disease modificationDisease modification
12
Figure quoted from: Hampel H et al. (2010)
13
Perspectives: Drugs in Development
Roberson and Mucke Science 314: 781 (2006)
Amyloid
Neurofibrillary tangles (NFTs)
Inflammation
Energy
Folding and removal
Competitive landscape Competitive landscape
14
Name Indication MoA Phase Estimated launch
Bapineuzumab* Mild to moderate ADHumanised monoclonal antibody to beta-amyloid
Phase III
Q3 2013 in US
Q2 2016 in Japan
Q2 2015 in 5EU
Gammagard* Mild to moderate ADPassive immunisation against beta-amyloid
Phase III 2015
LY2062430 (solanezumab)* Mild to moderate AD
Passive immunisation against soluble beta-amyloid
Phase IIIQ3 2013 in US and 5EU
ELND005 (scyllo-inositol) Mild to moderate AD
Beta-amyloid aggregation inhibitor
Phase II Q3 2014
MethylthioniniumChloride
Mild to moderate AD Tau aggregation inhibitor Phase IIQ1 2015 in US and Europe
Davunetide
AD, mild cognitive impairment, frontotemporal dementia and cognitive impairment in schizophrenia
Tau hyperphosphorylation
inhibitorPhase II Not known
Tideglusib ADAD GSK-3 beta inhibitorGSK-3 beta inhibitor Phase IIPhase II Not knownNot known
SB-742457 Mild to moderate ADMild to moderate AD 5-HT6 receptor antagonist5-HT6 receptor antagonist Phase IIPhase II Q1 2015 (US, 5EU)Q1 2015 (US, 5EU)
15Unmet medical needsUnmet medical needs
• Disease modifying therapies
• Prevention of symptom development
• Therapies for behavioral problems
• Effective management of sleep
Plassman et al. Ann Int Med, 2008 148:427-34
ConclusionsConclusions
Alzheimer’s disease is the most common cause of dementia with major costs for individuals, families and society.
No current therapies prevent development of symptoms or modify disease progression.
The aging of the population will lead to a dramatic increase in the number of individuals with Alzheimer’s disease.
16
Recommended